A staggering $2,041,243,323 is the current stake held by PRIMECAP Management in Boston Scientific Corp (BSX). Seeing a firm of this pedigree move to an "Increased" position status suggests they are finding something compelling in the medical device manufacturer's current trajectory. This particular holding represents a 1.6071441734897687% weight within their overall portfolio, signaling a high level of conviction for such a large-scale operator.

PRIMECAP vs. D.E. Shaw

While PRIMECAP is signaling growth with their increased position, D.E. Shaw & Co is right there in the mix. They have allocated $1,278,212,606 to BSX, also flagging their move as "Increased." Interestingly, their portfolio weight for this ticker sits at 0.7685766382116077%. When you look at the disparity between a 1.6% allocation and a 0.76% allocation, you start to see the difference in how these two shops prioritize the same healthcare asset within their broader mandate.

PRIMECAP is playing it as a cornerstone of their health exposure, whereas D.E. Shaw treats it as a significant, yet more measured, component of their diversified holdings. It is worth tracking how these two giants manage their exposure if the stock price moves away from the current $44.65 level.

The New Kid on the Block

Then we have Cadian Capital Management, which just initiated a position valued at $10,667,500. For them, this is a "New Position" that commands a 1.2990084944281248% allocation in their portfolio. It is quite a contrast to the multi-billion dollar titans like PRIMECAP or D.E. Shaw, as Cadian is coming in with a smaller absolute dollar amount but a higher relative portfolio concentration than D.E. Shaw. This type of entry often signals a specific thesis being played out by smaller, more tactical funds compared to the passive, long-term compounding approach usually associated with the larger shops.

Whale Dynamics and Market Signal

The aggregate data across the three firms tracked here—PRIMECAP Management, D.E. Shaw & Co, and Cadian Capital Management—reaches a total 13F value of $3,330,123,429. That is a substantial concentration of capital behind a single ticker. With a whaleCount of 3, the institutional footprint is clear, though not broad. If you are watching screener trends, keep an eye on how these three move during the next filing period.

Portfolio Weight Analysis

PRIMECAP’s 1.6071441734897687% weight is the highest of the group, which paints them as the primary driver of institutional interest in BSX. Cadian’s 1.2990084944281248% is surprisingly high for an initial entry, implying they likely allocated a meaningful chunk of their dry powder to this specific healthcare play right out of the gate. D.E. Shaw, with their 0.7685766382116077%, appears to be using the ticker as a precision tool rather than a foundational bedrock, despite the raw dollar value being massive.

The fact that two out of three firms increased their positions—PRIMECAP and D.E. Shaw—while Cadian started fresh means there was zero selling activity reported among this specific cohort. This lack of selling pressure is an interesting data point for anyone trying to gauge the sentiment of sophisticated money managers toward the company's long-term prospects. Every dollar mentioned here reflects a specific capital allocation decision made by these managers, and the absence of any "Decreased" or "Closed" flags across the entire sample size is a notable indicator of confidence. Whether this aligns with the underlying fundamentals or a specific trend within the healthcare sector, the institutional behavior is consistent across the board. You can monitor further updates and potential changes to these positions as future data becomes available.

This report is not investment advice; 13F filings are delayed by up to 45 days.